



Prevalence of methicillin resistant *Staphylococcus aureus* in various clinical specimen at Kist Medical College and Teaching Hospital

Sweekrity Neupane, Bijendra Raj Raghubanshi, Ruchee Manandhar, Rajni lama

Department of Microbiology, KIST Medical College, Imadol, Lalitpur

Article History

Received : 09 Jan, 2023

Accepted : 12 Mar, 2023

Published: 18 May, 2023

Funding sources: None

Conflict of Interest: None

Online Access



Corresponding

Sweekrity Neupane
Department of Microbiology ,
KIST Medical College and Teaching
Hospital
Imadole, Lalitpur, Nepal.
Email: sweekritinep@gmail.com

Introduction

Staphylococcus aureus is among the most successful human pathogens. Since the 1960s, *S. aureus* strains have emerged resistant to the penicillinase-stable penicillins. This resistance is the result of a supplemental penicillin binding protein (PBP 2a) encoded by the chromosomal *mecA* gene. These strains are termed methicillin resistant *S. aureus* (MRSA) and are resistant to all beta-lactam agents. MRSA causes progressive, potential fatal diseases including life-threatening pneumonia, necrotizing fasciitis, endocarditis, osteomyelitis, severe sepsis, and toxinoses such as toxic shock syndrome. The most common risk factors of being colonized or acquiring an MRSA infection are; presence of an open wound and/or other dermatology

disease, presence of invasive devices (e.g. catheter), prolonged use of antibiotics, prolonged hospital stay, several admissions to hospital over a short period of time.

Antimicrobial resistance is a global threat and there is increase in antibiotic resistance in *S. aureus*. MRSA has emerged as an important human pathogen. Various studies from different parts of the world show an increase in the number of Methicillin resistant *Staphylococcus aureus* (MRSA). MRSA is one of the commonest causes of hospital-acquired infections throughout the world¹. European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) in January 2008 and had constructed significant antimicrobial

Abstract

Introduction: Antimicrobial resistance is a global threat and there is increase in antibiotic resistance in *S. aureus*. Multidrug resistance developed in *S. aureus* has been associated with an increase in morbidity and mortality of the patients in the hospital. The main objective of this study was to detect MRSA using phenotypic methods and to determine their antibiogram.

Methods: Various specimens received from September 2020 to september 2021 in Kist Medical College-Teaching Hospital were processed and all *S. aureus* isolates were included in the study. The isolates were identified by standard laboratory procedure. Cefoxitin was used to detect MRSA by the disk diffusion test. The antibiotic susceptibility pattern of all isolates was determined by modified Kirby Bauer disc diffusion method.

Results: A total of 5,198 samples (blood 1683, pus 130, swab 328, body fluid 849, urine 2208) from patients attending the Kist hospital for treatment were collected. From the total 5,198 samples 80 were confirmed as *Staphylococcus aureus*. Out of 80 *S. aureus* isolated 49 (61.3%) were found to be MRSA. All the *S. aureus* isolated was sensitive to vancomycin. Among 49 MRSA isolates 33 (67.34%) were MDR and among 31 MSSA isolates 4 (12.9%) were MDR.

Conclusion: This study showed a high prevalence of MRSA in tertiary care hospital. Regular surveillance of healthcare-associated infection and monitoring of antibiotic sensitivity pattern is mandatory to reduce MRSA prevalence in hospital. Present study shows that vancomycin remains the drug of choice for MRSA infection.

Keywords: MRSA, *Staphylococcus aureus*, Vancomycin

categories for each bacterium.² They have defined different levels of antibiotic non susceptibility as: Multidrug resistant (MDR) is defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Extensively drug resistant (XDR) is defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories). Pandrug resistant (PDR) is defined as non-susceptibility to all agents in all antimicrobial categories.

Methicillin resistant *S. aureus* is typically multidrug resistant and treatment options are limited to few antibiotics like teicoplanin and vancomycin. Detection of the resistance pattern is therefore an important support tool to antibiotic treatment guidelines and susceptibility surveillance of *S. aureus*. This data will be helpful to collate the current state of resistance pattern in Nepal. It will also help to devise treatment protocol for MRSA infections.

Methods

This is a retrospective cross sectional study and conducted at Kist medical college and teaching hospital. Ethical clearance was obtained from KISTMCTH Institutional Review Committee with IRC NO -078/079/56. *Staphylococcus aureus* isolated in microbiology lab from various clinical specimen collected from September 2020 to September 2021 is the study population. Inclusion Criteria included *Staphylococcus aureus* isolated from various clinical specimens (blood, bodyfluid, pus, wound swab, sputum, urine). Exclusion Criteria included the specimen without demographic data. All samples (blood, sputum, urine, pus and bodyfluids) of patients who attended the hospital for treatment were collected from various departments for culture after the treating clinician requested them. Collected samples were received at the microbiology laboratory for microbiological tests. Standard laboratory procedure and technique was followed for sample collection.

Identification of *S.aureus*

Samples were inoculated into McConkey's agar, blood agar and chocolate agar. Blood was inoculated in Brain Heart Infusion broth and sub culture on 24 and 72 hour on BA and McConkey's agar. Selective media for *S. aureus* was not used. The gram stained smear of the suspected colonies was observed under an oil immersion lens. Gram positive cocci in clusters were subjected to further biochemical tests. *Staphylococcus aureus* was identified by standard microbiological technique.³ Different biochemical tests such as catalase, coagulase were performed. Gram positive cocci (GPC) in clusters, which were also catalase positive, were

subjected to a slide coagulase test. Gram positive cocci and both catalase and coagulase positive, were considered as *S. aureus*. Those which were negative by the slide coagulase test were further subjected to a tube coagulase test and were considered *S. aureus* if were positive for both the catalase and tube coagulase tests. However, only first isolate was included in the study if the same patient had other samples (blood, pus, body fluid and sputum) positive for *S. aureus* with same antibiogram.

Antibiotic susceptibility testing of *S. aureus*

Antibiotic susceptibility tests of the *S. aureus* were performed by a modified Kirby–Bauer disk diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI 2012) on Mueller–Hinton agar.⁴ Antibiotic disks (Hi Media Laboratories, Pvt. Limited, India) such as cefoxitin (30 µg), ciprofloxacin (5 µg), erythromycin (15 µg), co-trimoxazole (25 µg), gentamicin (10 µg), amikacin (30 µg), clindamycin (2 µg), cloxacillin (5ug) and vancomycin (30 µg) were used for antibiotic susceptibility tests.

Identification of MRSA

Cefoxitin disc (30 µg) was used for identification of MRSA. Methicillin-resistant *S. aureus* isolates carry the *mecA* gene, which confers resistance to all beta-lactam antibiotics, including cephalosporins and carbapenems. Apart from using molecular methods to detect the *mecA* gene directly, the most accurate phenotypic test for the presence of the *mecA* gene in *S. aureus* is the cefoxitin disk diffusion test. According to the Clinical and Laboratory Standards Institute (CLSI), a zone of growth inhibition of ≥ 22 mm around the cefoxitin disk rules out MRSA; a zone size < 22 mm indicates that the *mecA* gene is present and the isolate should be reported as MRSA.⁵

Statistical analysis

Then data was first entered in MS excel and later data analysis was done in SPSS vs. 26. Data were summarized in frequency distribution table presenting both in number and percentages.

Results

A total of 5,198 samples (blood 1683, pus 130, swab 328, body fluid 849, urine 2208) from patients attending the Kist hospital for treatment were collected. From the total 5,198 samples 80 were confirmed as *Staphylococcus aureus*. *Staphylococcus aureus* were further tested for MRSA by using cefoxitin disc. The drug profile was tested for 10 different antibiotics.

Out of 80 *S.aureus* isolated 49 (61.3%) were found to

be MRSA (Fig 1). Higher number of MRSA was found in females (28) compared to males (21). Maximum number of MRSA (25) was seen among age-group >30. Among various clinical specimen MRSA(16) was mostly isolated from pus sample (Fig 2). Antibiotic sensitivity pattern of S.aureus showed a higher degree of resistance to many antibiotics such as ampicillin (88.8%), erythromycin (65%), clindamycin (58.8%) and cotrimoxazole (60%). All the S.aureus isolated was sensitive to vancomycin (table 1). Multidrug resistant (MDR) is defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Among 49 MRSA isolates 33 (67.34%) were MDR and among 31 MSSA isolates 4 (12.9%) were MDR (table 2).

Figure 1. Prevalence of MRSA




Figure 2. Distribution of S. aureus in clinical samples




Table 1. Antibiotic susceptibility pattern of S. aureus

Antibiotic susceptibility pattern of (S.aureus (n=80)			
Antibiotics	Sensitive	Intermediate	Resistant
Ampicillin	9 (11.3%)		71 (88.8%)
Cefoxitin	31 (38.8%)		49 (61.3%)
Cloxacillin	61 (76.3%)	19 (1.3%)	18 (22.5%)
Cotrimoxazole	30 (37.5%)	2 (2.5%)	(60%) 48

Clindamycin	33 (41.3%)		47 (58.8%)
Erythromycin	28 (35%)		52 (65%)
Gentamicin	55 (68.8%)	3 (3.8%)	22 (27.5%)
Amikacin	62 (77.5%)	4 (5%)	14 (17.5%)
Vancomycin	80 (100%)		

Table 2. MDR pattern among S. aureus isolates

Isolate	MDR	Non- MDR	Total
MSSA	4 (12.9%)	27 (87.1%)	31 (100%)
MRSA	33 (67.34%)	16 (32.66%)	49 (100%)

Discussion

The development of multidrug resistance by S. aureus is a public health concern. It has added to the burden of patient by prolonging hospital stay. Methicillin resistant S. aureus has been associated with an increase in morbidity and mortality of the patients in the hospital. According to data published by WHO in 2014, it showed greater than 80% of Staphylococcus aureus infections having MRSA.⁶

The present study showed the prevalence of MRSA to be 61.3%. Findings in our study are consistent with the other studies previously conducted from Nepal. In study conducted at CMS teaching hospital, Chitwan overall prevalence of MRSA was 68.0%.⁷ In a similar study conducted by Rijal et al in pokhara MRSA was isolated at the rate 75.5% from clinical samples.⁸ However, varying prevalence of MRSA has been reported from different parts of Nepal such as 26.1% in Dharan⁹ and 57.1% in Birgunj.¹⁰ The high prevalence of MRSA in this study might be due to readily available and irrational use of antibiotics by the patient without specific laboratory test.

Present study shows maximum number of S.aureus and MRSA isolation from pus among all clinical specimens. This might be due to S.aureus being the most common organism causing pyogenic infection. Other study also showed higher S. aureus from pus sample.^{9,11}

Drug resistance in S. aureus is mediated by complex genetic arrays such as the staphylococcal chromosomal cassette mec elements for methicillin. Other resistances against antibiotics like fluoroquinolones, linezolid and daptomycin have developed through spontaneous mutations and positive selection. Detection of the resistance pattern is, therefore, an important support tool for antibiotic treatment guidelines and susceptibility surveillance of S. aureus in places where susceptibility testing is not a routine. In our study S.aureus showed a higher degree of resistance to many antibiotics such

as ampicillin (88.8%), erythromycin (65%), clindamycin (58.8%) and cotrimoxazole (60%). The findings in this study have been consistent with the findings from studies conducted in other parts of Nepal.^{9,12} Our study showed that all MRSA isolates were sensitive to vancomycin. This is in consistent with various other studies.^{13,14,15,16} These findings suggest that vancomycin is the drug of choice for treating MRSA infections.

Present study shows alarmingly high rate of MDR strain among MRSA isolates (67.34%). Other Studies conducted in eastern and western part of Nepal previously have reported MDR- MRSA to be as high as 65-78%.^(14,17) In similar study in India showed the isolation of MDR-MRSA as high as 77%²³.

Conclusion

Our study showed higher prevalence of MRSA among clinical specimens, especially pus. The disk diffusion test by cefoxitin for MRSA is simple and cost effective method and can be routinely utilized in resource limited settings to identify these isolates. The prevalence of multidrug resistance was higher among MRSA compared to MSSA. This shows high burden of multidrug resistant organisms. Thus, multi drug resistance is challenging health status of people from this area. In this study, all isolates were sensitive to vancomycin. Thus vancomycin should be considered as a last resort for treatment of MRSA infections. Regular surveillance of MRSA and monitoring of antibiotic sensitivity pattern is mandatory to reduce MDR prevalence in the hospital. Antibiotic stewardship guidelines should be strictly followed in hospital to reduce MDR MRSA.

References

- San De N, Denis O, Gasasira MF, Mendonca C, Nonhoff MJS. Controlled Evaluation of the IDI-MRSA Assay for Detection of Colonization by Methicillin-Resistant *Staphylococcus aureus* in Diverse Musculoskeletal Specimens. *J Clin Microbiol* 2007;45(4):1098-101.
- Magiorakos A, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Infect Dis* 2012;18:268-81.
- Forbes BA, Sahm DF, Weissfeld AS. *Staphylococcus, Micrococcus and similar organisms*. Bailey Scott's *Diagn Microbiol*. 2007;12(Chapter 16):254-63.
- Franklin R, Cockerill MAW, Alder J. Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement. 2012;32(3)(M100-S22):70-88.
- Wayne P. National Committee for Clinical Laboratory Standards. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6*. NCCLS. 2003.
- Plata K, Rosato AE, Węgrzyn G. *Staphylococcus aureus* as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. *Acta Bio chimica polonica* 2009;56(4):597-612.
- Sanjana RK, Singh R, Chaudhary N. Prevalence and antimicrobial susceptibility pattern of MRSA in CMS Teaching Hospital. *Journal of College of Medical Sciences Nepal*. 2010; 6: 1
- Rijal KR, Pahari N, Shrestha B. Prevalence of MRSA in school children in Pokhara. *Nepal Med Coll J*. 2008; 10: 192-5. (PMID)
- Kumari N, Mohapatra TM, Singh YI. Prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) in a Tertiary-Care Hospital in Eastern Nepal. *JNMA J Nepal Med Assoc*. 2008;47(170):53-6
- Shakya B, Shrestha S, Mitra T. Nasal carriage rate of methicillin resistant *Staphylococcus aureus* among at National Medical College Teaching Hospital, Birgunj, Nepal. *Nepal Med Coll J*. 2010;12(1):26-9
- Pandey S, Raza MS and Bhatta CP Prevalence and Antibiotic Sensitivity Pattern of Methicillin Resistant-*Staphylococcus aureus* in Kathmandu Medical College, Teaching Hospital. *Journal of Institute of Medicine*. 2012;34: 13-17
- Mishra SK, Rijal BP, Pokhrel BM. Emerging threat of multidrug resistant bugs—*Acinetobacter calcoaceticus baumannii* complex and methicillin resistant *Staphylococcus aureus*. *BMC Res Notes*. 2013;6:98. doi:10.1186/1756-0500-6-98.
- Rajbhandari R, Manandhar SP, Shrestha J. Comparative study of MRSA and its antibiotic susceptibility pattern in indoor and outdoor patients in Bir Hospital, Nepal. *Nepalese J Microbiol*. 2003; 1: 62-5.
- Shrestha B, Pokhrel BM, Mahapatra TM. Phenotypic characterization of nosocomial *S. aureus* isolates in special reference to MRSA. *J Infect Dev Ctries*. 2009; 3(7): 554-60. [PMID]
- Niami TS, LeDell KH, Como SK et al. Comparison of community and health care associated MRSA infection. *J Amer Med Assoc*. 2003; 290: 2976-84. [PMID][DOI]
- Rajduraipandi K, Mani KR, Paneerselvem K, Mani M, Vaskar M, Manikandan P. Prevalence and Antibiotic Susceptibility pattern of MRSA: A multicentre study. *Indian J Med Microbiol*. 2006; 24: 34-8. [PMID]
- Rijal KR, Shrestha N, Pahari N, Shrestha B, Paudel B, Nepal A, Ghimire P, Rijal B. Methicillin resistant *Staphylococcus aureus* in patients visiting Western region hospital. *JIOM*. 2008;30(1):21-25
- Saikia L, Nath R, Choudhury B, Sarkar M. Prevalence and antimicrobial susceptibility pattern of methicillin-resistant *Staphylococcus aureus* in Assam. *Indian J Crit Care Med*. 2009;13:156-8